The White House is poised to finalize a rule with significant implications for Americans’ access to life-saving medications. The rule deliberates on the usage of “copay accumulators,” programs employed by health plans that prevent copay assistance from counting toward patients’ deductible or out-of-pocket maximums. Traditionally, when patients receive copay assistance from pharmaceutical companies, the assistance counts toward reducing their overall out-of-pocket expenses. However, copay accumulators change this dynamic, as the assistance from the drugmaker is not credited to the patient’s expense limits.
Last September, Judge John D. Bates of the U.S. District Court for the District of Columbia overturned a 2021 rule allowing the use of copay accumulators, a decision spurred by advocacy groups challenging the prior regulation enacted during the Trump administration. The ruling now restricts payers to only use these programs for brand-name drugs that have generic equivalents.
The Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) appealed the decision in November. Reacting to this, a bipartisan group of 19 U.S. senators urged HHS to drop the appeal, emphasizing in a letter the necessity to ensure Americans receive cost-sharing protections for their expensive medications.
Copay assistance is crucial for numerous patients with conditions like cancer, arthritis, hemophilia, multiple sclerosis, HIV, and hepatitis. Carl Schmid, Executive Director of the HIV+Hepatitis Policy Institute, highlighted the dire consequences for patients who, upon exhausting their copay assistance, are blindsided by unexpected and substantial medical bills. This often leaves them with stark choices: incur significant debt or forgo their medication.
Approximately half of all employer plans utilize copay accumulators, with Schmid indicating that such schemes siphoned nearly $5 billion in assistance from patients last year. The intentions behind these programs, according to Schmid, seem paradoxical, as they appear to mitigate high drug costs while simultaneously causing substantial harm to patients.
The timeline for the White House’s final decision on the matter remains uncertain, with Schmid suggesting it could materialize “any day now or several weeks.” This looming decision underscores the ongoing tension between pharmaceutical cost containment strategies and the pressing need to maintain equitable access to essential medications for all Americans.
For detailed information on this topic, visit the original article on MedCity News.